Case study
First-in-Class TNIK Therapies for Obesity
Challenge
Obesity remains without an FDA-approved therapy targeting TNIK, presenting a significant unmet need and an opportunity for a first-in-class treatment.
Solution & Impact
BIOPTIC AI achieved a 7.8% hit rate, identifying multiple novel chemical scaffolds with high potential for targeting TNIK. This advancement opens the door to pioneering obesity therapy, positioning us at the forefront of first-in-class drug discovery in this critical area.
Chemical spase
39B
Search time
4H
Tested
102 compounds
Total cost
$18K
Novelty (Tanimoto ECFP4)
max 0.4
Hit rate (<10 μM)
7.8%
Best hit
1.1 μM
Partner with Bioptic
Expanding the scope of your research.